Physiomics Regulatory News (PYC)

8 Apr 2008 07:01

Physiomics PLC08 April 2008 Physiomics plc The Magdalen Centre The Oxford Science Park Robert Robinson Avenue Oxford OX4 4GA UK Tel 01865 784980 Fax 08701 671931 08 April 2008 Physiomics plc ("Physiomics" or "the Company") Physiomics to present on Cyclacel Pharmaceuticals collaboration on Aurora Kinase research program at the Annual Meeting of American Association of Cancer Research ("AACR") Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, ispleased to announce that it will be participating in the 2008 AACR AnnualMeeting, taking place in San Diego, on 12-16 April 2008. Dr ChristopheChassagnole, Chief Operating Officer of Physiomics, will present the results ofa recent collaboration with Cyclacel pharmaceuticals Inc. (NASDAQ: CYCC, NASDAQ:CYCCP). It will be shown how Physiomics technologies have been used to support apre-clinical research program on a novel Aurora Kinase inhibitor CYC116 that hassince entered in a phase 1 clinical research program. The abstract ("Systemsbiology analysis of a novel Aurora kinase inhibitor: CYC116", No 1645) will bepublished in the 2008 Proceeding of the AACR and will be presented in the postersession "Cellular and Molecular Biology 16", scheduled for 8:00 am 12:00 pm on14 April. More information about the conference may be found at www.aacr.org For further information:Physiomics plc +44 (0)1865 784980Dr Christophe Chassagnole, COOE-mail: cchassagnole@physiomics-plc.comGrant Thornton Corporate Finance +44 (0)20 7383 5100Philip Secrett, Colin Aaronson About Physiomics plc Physiomics plc (AIM:PYC) is a computational systems biology services companyapplying simulations of cell behaviour to drug development to reduce the highattrition rates of clinical trials. As 80-90 per cent of all clinical drugcandidates fail to reach the market, estimates1 show that an overall ten percent improvement in success rates could reduce the cost of one drug'sdevelopment by as much as $242 million, from the current estimate of around $800million. Physiomics develops computational systems biology models to predict andunderstand cancer drug efficacy from pre-clinical research to clinicaldevelopment. Physiomics has created detailed mathematical models incorporatingmost important molecular events taking place during the human cell cycle andapoptosis processes. Physiomics developed SystemCell(R) technology, amulti-cellular environment software, which enables the simulation of populationof "virtual cells". Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in2004. For further information, please visit www.physiomics-plc.com SystemCell(R) is a registered trademark of Physiomics plc 1Tufts Centre Impact Report 2002 This information is provided by RNS The company news service from the London Stock Exchange